FierceBiotechBluebird, Celgene to share US costs, profits on lead cancer CAR-TFierceBiotechBluebird bio has pulled the trigger on an option to co-develop and co-promote the anti-BCMA CAR-T treatment, bb2121, with Celgene in the U.S. The move comes two … Continue reading
|
The Alliance for Regenerative Medicine Releases Complete Agenda for Sixth Annual Cell & Gene Therapy Investor Day
GlobeNewswire (press release) This year’s Cell & Gene Therapy Investor Day is expected to attract more than 350 attendees, including nearly 200 active investors and analysts. With presentations from more than 35 of the sector’s most promising companies, along with panels and … |
Phys.Org |
Novel synthetic biology technique could lead to breakthroughs in disease treatment
Phys.Org This work represents a significant development in synthetic biology, according to Wilson Wong, a biomedical engineering researcher at Boston University who was not involved in this research. Wong focuses on cellular immunotherapy—the use of the body’s … |
|
Speak Up About Immunotherapy’s Side Effects
Curetoday.com Sometimes patients may not report side effects to their health care team, in fear of their oncologist taking them off a drug that could prolong their survival. BY Brielle Urciuoli. PUBLISHED March 28, 2018. Sometimes patients may not report side … |